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Plasmodium falciparum is a devastating disease. Though different interventions 
are employed every year, the burden persists, leading to 219 million cases and 435,00 
deaths in 2017. The malaria affected regions rely heavily on the anti-malarial drugs such 
as artemisinin-based combination therapies, and vector control methods. However, recent 
reports have documented parasites resistant to quinolines and artemisinin-based drugs, 
and vectors that are resistant to insecticide treatments.  
Though decades of research on malaria research has yielded a licensed 
RTS,S/AS01 malaria vaccine in 2015, the vaccine efficacy only provides a moderate 
vaccine efficacy (35.9%) in its first year, and wanes completely by year 5. With the 
increasing reports of resistance in anti-malarial drug and vector control methods, there is 
a clear evidence for a need of new interventions such as improved vaccines or 
prophylaxis.  
From reports of past and present on immune response against irradiated 
sporozoites in different animal models and humans, as well as data from the phase 3 
clinical trial of RTS,S/AS01, the correlate of protection from sporozoite infection points 
to neutralizing antibody against the CSP antigen. Extrapolating from the findings, 
increased amount of CSP neutralizing antibody for an extended period would serve as an 
ideal vaccine against malaria.  
We have investigated expression of high levels of monoclonal antibodies for an 
extended period by using the vectored immunoprophylaxis (VIP)  system through the 
recombinant Adeno-associated Virus (rAAV) vector and testing malaria protective 
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efficacy using different animal models. In this thesis we have investigated protective 
immunity of VIP-AAV induced antibodies that have been recently discovered through 
Controlled Human Infection Model (CHIM). In transduced mice, MGU-12 monoclonal 
antibody was expressed at a high concentration and elicited 50% protection.  
In preparation for protection challenges, we have characterized VIP-rAAV 
expression kinetics in a non-human primate Aotus nancymae monkeys. When injected 
with 1x1013 GC of 2A10-VIP-rAAV, 2/6 monkeys had consistent expression of 2A10 
antibodies for >30 weeks while 4/6 Aotus monkeys had only transient antibody titers at 
around week 3-6. Our results show that improved antibodies can lead to higher rate of 
protection in VIP-rAAV model but that additional strategies to improve antibody 
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Burden of Malaria and Human Malaria Lifecycle 
Malaria is a severe febrile illness caused by genus Plasmodium parasites with 
symptoms that range from fever, splenomegaly and anaemia to cerebral malaria and 
death [1]. The parasite is transmitted from person/animal to person by female Anopheles 
mosquitoes [1]. Though different methods of interventions are employed every year, the 
burden still persists and in 2017, 219 million cases were reported, with 435,00 deaths [1].  
Of those, 92% of the malaria cases and 93% of deaths occurred in WHO African Region, 
61% of the deaths occurring in children under 5 years [1]. The pathogen also incurs 
economic burden, as an estimated $3.1 billion was spent in 2017 by endemic 
governments and international partners in an effort to alleviate the disease burden [1].  
The malaria affected regions rely mainly on the anti-malarial drugs such as 
chloroquine and artemisinin-based combination therapies, and vector control methods. 
However, recent reports have documented parasites resistant to quinolines and 
artemisinin-based drugs, and vectors that are resistant to insecticide treatments [2, 3]. 
With the trend of diminished decline of malarial burden with increasing funds used on 
current prevention / treatment methods [4] and reports of resistance in anti-malarial drug 
and vector control methods, the need for a new intervention such as vaccines or 
prophylaxis is evident.  
Plasmodium falciparum lifecycle within the host and rationale for pre-erythrocytic stage 
vaccine 
The genus Plasmodium is a single-celled parasite known to infect different 
organisms including reptiles, birds and mammals and notably, humans [5]. Five 
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Plasmodium species have been identified to infect humans, P.malariae, P.ovale, P.vivax, 
P.knowlesi and P.falciparum [5]. Species P. falciparum has been identified as the largest 
portion of the burden, and is responsible for febrile Malaria in 99.7% in WHO African 
Region, 62.8% in Southeast Asia, 69% in Eastern Mediterranean and 74.1% in WHO 
Americas [4]. 
The P.falciparum has a multi-stage complex lifecycle in the vertebrate host as 
well as the vector host. It changes into many morphologic forms that allow the parasite to 
carry out its appropriate task in a specific stage of infection. From the vector mosquito’s 
salivary gland, the sporozoite form enters the dermis lingers at the site of injection for 
about 1-3 hours [6-8]. The sporozoite is in constant state of movement, and its gliding 
movements and Trap-Like Protein (TLP) allow for penetration from dermis into the 
blood vessel. While circulating in the blood, sporozoite crosses the sinusoidal barrier in 
the liver using the sporozoite microneme protein essential for transversal (SPECT), 
SPECT2 or also known as perforin-like protein-1, cell transversal protein for ookinetes 
and sporozoites (CelTOS), Phospholipase (PL) and gamete egress and sporozoite 
traversal protein (GEST) [9]. Upon interaction with the hepatocytes, the sporozoite 
‘switches’ from migratory mode into invasive mode. Upon contact with the hepatocytes, 
the thrombospondin-related anonymous protein (TRAP), apical membrane antigen-1 
(AMA-1) protein and circumsporozoite (CS) protein work in collaboration permit the 
parasite to enter the cell. Within the liver, or the exo-erythrocytic form, the parasite 
replicates and in 2-10 days, up to 40,000 merozoites erupt from each hepatocyte and enter 
the bloodstream [9]. 
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In the erythrocytic stage, the released merozoites attach themselves to 
erythrocytes by forming a tight junction through AMA-1 and RON complex and 
efficiently enters the cell through sequence of lipid-rich rhoptry contents and actomyosin 
motor. The pore created by the entry is sealed subsequently by the fusion of membranes 
in the posterior end of the merozoites [9, 10]. Within the erythrocyte, the merozoite 
undergoes replication (schizogony) and in 48 hours, it ruptures the cell releasing 16-32 
merozoites into the blood stream for further infection [9]. Some of the released 
merozoites can develop into male (microgamete) or female (macrogamete) form of 
gametocyte, the sexual stage of malaria [9]. The sexual maturation of the gametocytes 
takes about 11 days, in which time, they are sequestered within the bone marrow to avoid 
the clearance by the spleen and the host immune system [9]. The mature gametocytes 
then are taken up by the female Anopheles mosquito vector in the peripheral circulation 
and fuse to form a zygote and subsequent genesis of sporozoites to restart the replication 
in a host [9]. 
Vaccination efforts have mainly focused on pre-erythrocytic stage vaccines 
targeting prevention of sporozoite invasion into hepatocytes and replication within liver 
stage and erythrocytic stage vaccines against asexual merozoites [11, 12]. Although 
intervention in each stage is beneficial to the host, immune responses against the pre-
erythrocytic and sporozoite form is most advantageous because it prevents the overall 
infection in the host, as well as replication and transmission of the parasite [13]. 
Additionally, investigations on mosquito sporozoite injection showed that as few as 20-
120 sporozoites were injected into the dermis [14] and of those, at least 20% were 
drained into the proximal lymph nodes where they are degraded subsequently [6, 15]. 
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This suggests that there is a bottleneck effect at the site of dermal inoculation [7] that 
could potentially provide the most efficient intervention at the pre-erythrocytic stage, 
given that the sporozoite also lingers at the site of injection between 1-3 hours [6]  
Investigations of vaccination using sporozoite was first exploited against murine 
malaria Plasmodium berghei that was attenuated through x-ray radiation of the mosquito 
vector, which was successful in inducing humoral immune response that was able to 
neutralize the invasion of sporozoites [16]. The same attenuated sporozoite vaccination 
strategy was applied to the human malaria species P. falciparum, and showed proof-of-
concept of sterile immunity through humoral immune response against the pre-
erythrocytic stage of the parasite [17].  
However, as general consensus that natural infection does provide partial 
protection but not sterile immunity, and the immune response was much dependent on 
age and dose-dependent [11], different antigens in the pre-erythrocytic stage has been 
targeted to elicit a more robust and specific immune response. Antigens that have been 
identified as a potential target include antigens that are involved in the sporozoite motility, 
such as CelTOS antigen expressed in the motile stage of the sporozoite and ookinete [18] 
and Thrombospondin-related adhesive protein (TRAP)  protein that is highly involved in 
enabling motility from the skin into the hepatocytes [19-22] and Liver Stage Antigen-1 
(LSA-1) antigens that are expressed on the early stages of infection in hepatocytes unique 
to the P.falciparum species [23]. Preliminary studies have already shown that motility 
targeted antigens and liver stage antigens have been successful in eliciting partial 
protection [24-26].  
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Of the antigens under scrutiny, repeatedly the most well described and 
immunodominant antigen is the circumsporozoite protein (CSP) [13]. CSP antigen was 
identified as an antigen in both human and rodent malaria sporozoites [27] and antibodies 
directed against the CSP has been identified to have the highest affinity towards the 
sporozoite in an competitive assay [28]. Antibodies directed against the CSP antigen has 
been suggested to affect the sporozoite’s motility, shown from the differences in net 
displacement in the presence of the anti-CSP antibodies [7]. Specifically, the most 
immunodominant epitope in the CSP has been identified as the NANP repeat region [13] 
which is also conserved throughout the P.falciparum species around the world [13, 29], 
and have been branded as an ideal target for vaccine development [13].  
 
CSP and RTS,S/AS01  
CSP is the most abundant surface protein on the sporozoite. From the sporozoite 
surface, the CS is composed of glycosylphosphatidylinositol (GPI) signal, TSR domain, 
the C-terminus, the central repeat region, Region 1, and the N-terminus [30].  It is highly 
sought after in the quest for vaccines as immunodominant response is elicited against the 
repeat region of the CSP [13]. The CSP is highly relevant in the invasion of sporozoite 
from the site of injection into the hepatocyte as the CSP undergo conformational change 
in different phases [31, 32]. In the migratory phase of the sporozoite, the N-terminus 
masks the adhesive C-terminal domain and upon contact with a hepatocyte, it changes its 
conformation to invasion phase, where the C-terminal cell-adhesive domain is exposed. It 
is the proteolytic cleavage of CSP occurs in the highly conserved region I by the papain 
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family cysteine protease that converts from the CSP migratory to invasion phase, and it 
has been suggested that CSP is essential in invasion into the hepatocyte [31, 32].  
RTS,S/AS01, the vaccine in the most advanced stages of the clinical trial uses a 
portion of the CSP in its formulation [33]. Specifically, RTS,S is a two part vaccine 
where the C-terminal half of the CSP fused to the hepatitis B virus surface antigen 
(HBsAg) is expressed into virus-like particles (VLP) that display CSP and HBsAg on its 
surface. In addition, the CSP and HBsAg (RTS) is expressed with pure HBsAg (S) 
formulation in 1:4 ratio [34]. The antigens are expressed from genetically engineered 
Saccharomyces cerevisiae yeast cells and its novel adjuvant systems AS01 was 
developed to elicit a more robust and longer-lasting immune response [34].  
In a phase 2a clinical trial, 50% of the vaccinees were protected and the anti-CS 
titer rose to a high level. Anti-CS antibody was a correlate of protection, as protected 
individuals had over 2-fold titers than the unprotected individuals [35]. Encouraged by 
the data, the vaccine was used in an endemic population for the phase 3 clinical trial in 
children 5-17 of age, followed up to 7 years for vaccine efficacy. In relative similarity to 
phase 2 clinical trial, in the first year of the trial, the efficacy of the vaccine was 35.9% 
(8.1-55.3%, 95%CI) [36]. However, the efficacy after 7 years declined to just 3.6% (-
29.5-28.2, 95%CI), and negative efficacy was observed in the 5th year of surveillance 
[36]. Investigations into the clinical trial lead to a few conclusions, including the 
mismatched strain of P.falciparum in the area [37], minimal T-cell immune response, and 
the endemicity of the population where the semi-immune status of the endemic 
population that may have worked adversely and prevented full immune response against 
the vaccine [11].  
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Though RTS,S/AS01 has been licensed by the European Medicines Agency 
(EMA), lessons from the RTS,S/AS01 have encouraged research in different forms of 
CSP vaccine candidates, such as R21, identical in RTS,S construct but increased ratio of 
the CSP-HBsAg to HBsAg (S). The basis of the vaccine is to concentrate on increasing 
the anti-CSP antibody with a higher ratio of RTS,S at lower overall dose and have 
entered phase 1/2a clinical trials [38].  
Some of the main emphasis from the RTS,S/AS01 clinical trials was waning in 
vaccine efficacy/immune response and antibody-mediated protection [36]. From the 
RTS,S/AS01 phase 3 randomized trial, the protective immunity was correlated with 
presence and level of antibody against sporozoites [39, 40]. Though statistical evidence 
model provides that combined antibody and cell-mediated immune response provide 
better fit to protection, (Immune response of antibody alone estimated 32% protection 
(24-41% CI 95%) and 40% with CSP-specific CD4+ T-cell response) [39] the presence 
of neutralizing antibodies alone provided the major correlate of protection [39]. This 
conclusion is not surprising however, as past experiments using sera from humans and 
animals vaccinated with attenuated sporozoite have shown that anti-CS antibodies could 
neutralize and inhibit sporozoite and its invasion in vitro and in vivo [13, 41, 42]. As CSP 
is heavily involved in motile and invasion function of the sporozoite and the proteolytic 
cleavage site is close to the NANP central repeat antibody-binding sites, some of the 
monoclonal antibodies (mAbs) have been identified to interfere with the functions of the 
CSP and inhibit sporozoite infection [43].  
Though passive transfer of antibodies is the most efficient method of prevention 
of infection and transmission [44], and would be a valuable asset in combating malaria, 
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the duration of its half-life, production line, delivery system and logistical hindrance is a 
big obstacle for use in malaria endemic areas. However, an alternative method of 
antibody transfer in recombinant Adeno-associated Virus sheds a light in innovative 
method of delivering mAbs.   
 
Adeno-associated Viruses 
Adeno-associated Virus (AAV) is a Dependoparvovirus in the family of 
Parvoviridae [45, 46]. It is an unenveloped DNA virus with a icosahedral capsid about 
26nm in size [46]. The virus capsid is composed of capsid protein VP1-3, in 1:1:10 ratio 
– totaling 60 proteins per virus particle [45]. Its genome is about 5kb and can carry plus 
or minus sense single stranded DNA viral genome [45]. The DNA genome is flanked by 
inverted terminal repeats (ITR) that form a T-shape secondary structure and contains the 
origins of replication and packaging signal [45, 46]. The DNA genome only has two open 
reading frames, the rep and cap genes. Rep encodes 4 replication genes rep78, rep68, 
rep52, rep40 and cap encodes VP1-3 and Assembly Activating Protein (AAP) that 
promote virion assembly [46, 47]. These proteins are translated through alternative 
splicing and use different initiation codons [45, 46].  As the name suggests the virus 
depends on adenovirus or herpesvirus for essential proteins and molecules for replication, 
assembly and egress [45, 46].  
AAVs are founds in multiple vertebrates including humans. Human AAVs are 
closely related to primate AAVs [45]. AAVR (KIAA0319L) protein is an receptor 
protein for multiple serotypes of AAV [48-50] and has also been characterized as a 
facilitator in intracellular trafficking [50]. The virus is internalized through endocytosis 
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[51], and pH dependent structural changes and viral DNA is released into the nucleus [52] 
by the use of cytoskeletal network [53]. Generally, the AAVs are not known to cause 
human diseases although there is a low tendency for the virus genome to integrate itself 
into a AAVS1 site in chromosome 19 to establish a latent form [54].  
Recombinant AAVs or rAAVs are AAVs that have the exact same capsid but 
carry a therapeutic expression cassette in place of the of its rep and cap genes [45]. The 
only conserved viral genome is the ITR that is essential for virus replication and 
assembly during transfection for vector production [45]. The virus replication cycle 
enables complete replacement of the genome (up to 5kb [55] and allows for expression of 
foreign genes in infected cells. Widely used serotypes for rAAVs have been well 
characterized in receptor recognition, as receptors such as glycoproteins dictate its tissue 
and cell tropism[45]. After the transgene has been released into the nucleus by 
endocytosis, the double strand forms a circular rAAV intermediates that remain as an 
episome and allow long-term transgene expression [56]. This is one of the rate-limiting 
steps in transgene expression because the virus must complement its DNA with a 
leading/second strand synthesis [57, 58]. To eliminate the rate limiting step, single-chain 
AAV or scAAV are made to skip the DNA strand synthesis [59] and higher yield of the 
expression of the transgene. However, the high yield comes at a cost as the scAAVs can 
only accommodate half the transgene size[45, 59].  
The first ever rAAV product licensed is Glybera, alipogene tiparvovec, that is 
used as a gene replacement for treating lipoprotein lipase deficiency [60]. The first rAAV 
product licensed in the US is Luxturna (Voretigene neparvovec-rzyl) that is used also as a 
gene replacement for defective RPE65 gene [61]. Different rAAV strategies exist, 
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including gene-silencing for monogenic toxicity genes, gene-editing using CRISPR-Cas 
or Zinc-finger nuclease technology and gene-addition for expressing higher concentration 
of molecules for chemical imbalance, or for prevention of infectious diseases.  
 
rAAV VIP and Anti-CSP monoclonal antibodies (mAbs) 
 
From clinical trials of RTS,S/AS01 and vaccinations with irradiated sporozoites 
in animal and human model, it was evident that antibody against the sporozoite / CSP 
was the most accurate correlate of protection [39, 40] and that traditional vaccines had a 
limited efficiency over the longer periods due to waning immunity [36]. As an innovative 
and possible alternative against observed immune response from  traditional vaccines, 
rAAV has been engineered to express antibody transgenes in infected cells [62-67].  
The transduction of antibody transgene is termed vectored immunoprophylaxis 
(VIP) and the VIP system is aimed to express antigen specific mAbs for an extended 
period to prevent infection or intervene further infection[62]. The VIP system uses 
wtAAV derived plasmid backbone, however, the ITR region is the only remaining viral 
DNA viral gene having been replaced by optimized genes for efficient mAb gene 
expression, including cell-specific promoter, poly-adenylation signal, and post-
transcriptional enhancer [62, 65, 66] (Fig. 1). The rAAV-VIP system has been tested 
against epitopes on various pathogens and has provided sterile immunity through its 
antibody expression, including broadly neutralizing antibodies (bnAbs) against gp-120 on 
HIV-1 [62, 64, 67], hemagglutinin on influenza[63] and CSP (NANP repeat). on the 
sporozoite stage of P.falciparum [65].  
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In rAAV-VIP system against CS surface protein on the sporozoite stage of 
P.falciparum, antibodies 2A10 and 2C11 [28], were expressed in murine model [65]. The 
expression levels were dependent on the virus genome copies (GC) injected 
intramuscularly and mAbs concentration over 1000ug/mL were observed after 4 weeks. 
Protective immunity from mosquito delivered sporozoites was observed in 60% of the 
rAAV expressing 2A10 mAbs, and 30% of the mice expressing 2C11 mAbs. In 
accordance with antibody levels as correlate of protection observed from clinical trials, 
mice expressing high level of 2A10 mAbs (>1000ug/mL) had 100% protection rate, 
while lower level of mAbs expression showed varying level of protection [65].  
Clinical trials of human immunization with irradiated P.falciparum sporozoites 
has yielded in multiple potent antibodies that also target the CSP in the sporozoite stage 
of the human malaria [68, 69]. mAbs named CIS43 isolated from protected individuals 
provided the highest protective effect against the liver-stage parasite burden in mice, and 
also showed the highest level of protection than even previously mentioned 2A10[68]. It 
was most notable in that though the antibody titer was lower in mice with CIS43 than in 
mice with 2A10, higher level of protection was observed in mice with CIS43 [68]. MGU-
12 was also isolated from CHIM, and in murine model, it also showed high protective 
effect in liver-stage burden [69]. While the two isolated antibodies are impressive in that 
they show highly protective effect against sporozoite challenges, it is most intriguing that 
the binding site for these antibodies are at the “junctional epitope” between the N-
terminus and central repeat region, diverging from the immunodominant central NANP 
repeat region, a region that is not included in the RTS,S/AS01 formulation. In this thesis, 
we report the expression and protective efficacy of rAAV of newly described CSP-
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directed antibodies and analyze the vector and VIP expression kinetics. The protective 
efficacy of new antibody expressing rAAV are tested in murine model as to compare with 
formerly analyzed 2A10 mAbs [65].  
In addition, the formerly described rAAV-VIP system of 2A10 mAbs will be 
translated into nonhuman primate model in an effort to more accurately observe 
expression kinetics and protective efficacy in an animal model resembling human 
immune system and address possible safety issues. The rAAV expression and malaria-
mosquito challenge will be conducted on Aotus nancymae monkeys that can uniquely be 
infected by human P.falciparum[70, 71] and are an accurate portrayal for human 












Figure 1. VIP Modular expression cassette 
Red arrows: AAV inverted terminal repetition sequences containing AAV replication and 
packaging signals for vector production. Gray rectangles: IgG variable regions. These are 
flanked by unique restriction sites (not shown) to facilitate replacement to generate antibody 
genes with new specificities. Yellow rectangle: Self-cleaving peptide that cleaves the primary 
translation product into native heavy and light chains. Green bars: export signal sequence. The 
remaining elements, WPRE, SD, SA etc., are regulatory sequences that drive efficient mAb gene 























Materials and Methods 
 
Vector Plasmid Construct and Cloning 
The published 2A10 (anti-CSP NANP repeat region) and b12 (anti-HIV-1 gp120 
protein) DNA sequences were cloned into the VIP expression cassette by Dr. David 
Baltimore’s Laboratory at California Institute of Technology [62] and its protective 
efficacy against HIV-1 and P. falciparum parasites were previously tested by the 
Baltimore Laboratory [62] and our laboratory [65] respectively. In this thesis, b12 
antibody was used as a negative control and 2A10 was used as a positive control antibody 
with a repeated and stable protective rate [65].    
As described, the monoclonal CIS43 and MGU12 antibodies both specifically 
bind to the junctional region of the CSP between the N-terminal peptides and NANP 
peptide repeat region. CIS43 binds to an epitope 15-mer N’-NPDPNANPNVDPNAN-C’ 
(Peptide 21) (Fig. 2) and MGU12 binds to 15-mer N’-KQPADGNPDPNANPN-C’ 
(NPDP15) (Fig. 3) 
To clone the variable regions (referred to as inserts) of the two antibodies into the 
existing 2A10 VIP vector the published Heavy (VH) and Kappa (VK) inserts were first 
synthesized by Thermo Fisher Invitrogen GeneArt Gene Synthesis. Endonuclease 
restriction sites NotI and AgeI flanked VH and NsiI and PstI flanked VK for 2A10 VIP 
vector, and the GeneArt CIS43 and MGU12 heavy and kappa inserts were also flanked 
with the respective endonuclease restriction sites.  
For CIS43 cloning into VIP vector, 5ug of GeneArt CIS43 and 2A10 VIP plasmid 
DNA were separately incubated with NotI and AgeI each for VH region. The mixture was 
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incubated at 37°C for 4 hours. After incubation, the mixture was ethanol precipitated. The 
ethanol precipitation steps are: 1) addition of 2.5X volume of 100% EtOH 2) place on ice 
for 15 minutes 3) centrifuge for 15 minutes at 14,000rpm 4) aspirate the supernatant 5) 
dry the precipitate for 15 minutes, and 6) add desired final volume of TE.   
Both digested plasmids were mixed with 6X Blue Gel Loading Dye (NEB) and 
loaded on to a 1% agarose gel containing 0.5ug/mL ethidium bromide and 0.5ug/mL 
ethidium bromide TE running buffer at 50mA alongside a 1kb Plus Ladder (NEB). The 
VIP vector (minus the 2A10 VH insert) and CIS43 VH insert  were separated by the gel 
and were subsequently extracted from agarose gel using QiAquick Gel Extraction Kit 
(Qiagen) and saved for the ligation reaction. The extracted linear DNA concentration was 
measured at 260nm wavelength.  To ligate the VIP vector and CIS43 VH insert, the 
plasmids were added at a 1:1 molar ratio with DNA Ligase I. The mixture was incubated 
at 37°C for 4 hours.  
Bacterial transformation was conducted with DH5-alpha cells (Subcloning DH5-a 
competent cells by Thermo Fisher Scientfic) according to manufacturer’s instructions. 
The transformed DH5-a were plated in 60 ug/mL ampicillin Agar and incubated at 37°C 
overnight to screen for the VIP plasmid transformed isolates which contain ampicillin 
resistance gene.  
Isolates of transformed cells were grown in in Luria Broth at 37°C overnight, and 
Qiagen Mini/Midi Kit (Qiagen) was used to extract pDNA and its concentration was 
measured with nanodrop at 260nm wavelength. 
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To confirm the ligation of CIS43 VH variable region into the VIP vector, 
endonuclease reaction with DraIII was conducted to determine the presence of the 
restriction sites that could differentiate between the 2A10 and CIS43 variable regions 
(Fig. 5A). The cloning procedure for the second variable site, VK, did not yield in a viable 
copy, therefore NEB Builder Gibson Assembly Kit (New England BioLabs) was used to 
for VK cloning. Once the ligation of both CIS43-VH and VK was confirmed by DraIII and 
KpnI endonuclease activity unique to CIS43 VH and VK, (Fig. 5B) the plasmid was 
sequenced by Johns Hopkins Sequencing Core for further confirmation 
For the MGU12 construct, both of the variable regions were cleaved and ligated 
simultaneously using the NEB Builder Gibson Assembly Kit (New England BioLabs). 
The MGU-12 construct was also transformed into DH5-a cells, screened by ampicillin 
resistance, its DNA extracted by Qiagen Mini/Midi Kit (Qiagen) and sequenced at Johns 
Hopkins Sequencing Core to confirm the MGU-12-VIP plasmid.  
 
Comparative Functionality of CIS43 and MGU12 Vector Plasmid 
To assess the functionality and measure the antibody expression levels of the 
CIS43 and MGU12 VIP construct, the VIP plasmids were transfected in 293T cells, and 
antibody titers were measured by ELISA against hIgG and rCSP. 2A10 VIP plasmids 
with known functionality and levels of expression in vitro and in vivo, were transfected as 
a comparison. 
For plasmid transfection, 300,000 HEK-293T cells were plated 48h prior to 
plasmid transfection to achieve 75% confluency in a 6-well plate. The cells were grown 
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in Dulbecco’s Minimum Essential Media (DMEM). Two hours prior to plasmid 
transfection, the media was changed to D10 (DMEM containing 10% Fetal Bovine 
Serum, 1% Penicillin/Streptomycin, and 1% L-glutamine) 
Appropriate volume for 2ug of DNA and 3uL of BioT (Bioland Scientific LLC) 
were mixed with 100ul of serum-free DMEM, centrifuged briefly and incubated at room 
temperature for five minutes. The mixture was then added to each well plate, and gently 
stirred. 100uL samples were collected 24 hours and 48 hours post transfection and 
quantified for human IgG by ELISA as described [62]. 
 
rAAV Production and Purification 
Three days prior to AAV plasmid transfection, 3.75x106 HEK 293T cells were 
plated in Nuclon Delta Surface 15cm plates (Thermo Scientific) with D10 media. 2 hours 
pre-transfection, the media was replaced on the 15cm plate with fresh D10. In a 50ml 
Centrifuge Tube (Corning), 24.6ug of AAV VIP plasmids (2A10, CIS43, MGU-12 or 
b12), 98.4ug of pHELP helper plasmid (Applied Viromics LLC), and 197ug of AAV 
plasmid that contains replication genes from AAV2 and capsid gene of AAV8 (AAV2/8), 
and 240uL of BioT(Bioland Scientific LLC) were mixed with 16ml of DMEM and 
incubated at room temperature for 5 minutes (Fig.4 ). The ~16mL of pDNA and BioT 
were separated into 15cm plates. 
The media culture containing the virus was collected at 36, 48, 72, 96, 120 hours 
post transfection and filtered through a 0.22um PES Membrane Stericup Quick Release 
(Millipore). The supernatant was saved in 4C cold room for virus purification. 100uL of 
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supernatant was set aside to assess virus production at each timepoint. ¼ volume of 5X 
Polyethylene Glycol (Promega) was added to the virus supernatant and allowed to 
precipitate overnight.  
The PEG precipitated virus was divided into two and centrifuged (Sorvall RC5C 
Centrifuge) at 5000rpm for 30 minutes, and the supernatant was discarded. Each tube of 
virus was resuspended in 5ml of Cesium Chloride (Research Products International) 
solution of 1.37g/mL density. The virus in Cesium Chloride (CsCl) solution was 
combined with additional 10ml of CsCl solution, a total of 20mL. The virus was then 
equally distributed into Quick-Seal Ultracrimp Tubes 11.5mL (Thermo Scientific) with 
Pasteur pipettes. Additional CsCl solution was added up to the neck to completely rid of 
bubbles. The Quick-Seal Ultracrimp Tubes were then sealed with cap and sealer (Thermo 
Scientific). The tubes were placed in Sorvall WX Ultra Series (Thermo Fisher Scientific) 
and spun in an ultracentrifuge at 60k, 20'C, for 20+ hours.  
The Quick-Seal tubes were recovered from the ultracentrifuge and clamped onto a 
stand. 20G needles were used to pierce through the center of the bottom curvature and 
removed. Below the neck of the Quick-seal tubes were pierced with 27G needles and the 
butt-end was blocked with a finger to stop the flow of the tube content. To collect the 
flow-through from the bottom of the tube with a 96-well plate, the 27G needle was 
manually controlled to allow constant drip of the CsCl mixture solution. Each well was 
then checked for density through a refractometer and recorded. Because the properties of 
AAV particles are known, wells that were 1.3755> X > 1.3655  on the refractometer 
index range were pooled for the dialysis step. 
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For dialysis of the rAAV, the CsCl solutions from the 96 plate wells were 
transferred into the Amicon Ultra (Merck Millipore) filter tubes. Additional TFB2 was 
added to fill up to 15ml in the Amicon filter tube, and the mixture was centrifuged for 
3000 rpm, 4C for 1 hour. The flow-through was centrifuged for about 1 hour or until the 
liquid in the filter was less than 1ml. The flow-though was discarded and additional 
TFB2 was added to the filter up to 15ml. The TFB2 and centrifuge was repeated three 
times until the retentate was less than 500uL. The retentate was then used to rinse the 
filter on the Amicon Ultra filter tube to and all the retentate was collected and frozen at -
80'C.  
rAAV Quantification 
AAV quantification was conducted as described previously [62] using PCR. The  
sample rAAV and the standard (AAV8 expressing b12 mAb with the concentration of 
1x1012 GC/mL)  were both diluted 10-fold in DNAse/DNAse buffer and incubated at 
37°C for 30min. For the negative control, instead of the sample, DEPC treated water was 
added(Promega) and incubated. 7 dilutions were made for the standard which was diluted 
4-fold with DEPC treated nuclease free water(Promega). The sample rAAV was diluted 
three times, a 100 fold and two subsequent 10 folds. The negative control was not diluted.  
The PCR mastermix composed of 78.75% CYBR-Green PCR Mastermix 
(Thermo Fisher), 19.95% DEPC treated nuclease free water, 3.15% forward and 3.15% 
reverse CMV promoter primers (5′ CMV: AACGCCAATAGGGACTTTCC and 3′ CMV: 
GGGCGTACTTGGCATATGAT). 10uL of the master mix and 5uL of either standard, 
negative control or rAAV sample was loaded onto MicroAmp Fast Optical 96-well 
Reaction Plate (Thermo Fisher). Each sample was quantified using qPCR (Applied 
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Biosystems One Step Plus qPCR) with the following program: 1X 50°C for 2 minutes, 
1X 95°C for 10 minutes and 60X of 95°C for 15 seconds and 60°C for 60 seconds.  
 
Mouse rAAV injection and serum collection 
Quantified recombinant viruses were thawed and diluted with TFB2 to achieve 
1x1011 genome copies (GC) or 3x1011 GC in 100uL volume. 1/2cc Insulin syringes (BD) 
were used to inject 50uL of TFB2 diluted viruses into gastrocnemius muscle (i.m.) in 
each hind leg. 4-6 week old female C57BL6 mice were used in groups of 10 with 
different recombinant AAV. Post i.m. injections, blood was drawn at different time points 
through cheek-bleeds. Sera was separated by BD Microtainer SST (BD) tubes at 
5,000rpm for 10 minutes, and stored at -80°C.  
 
Aotus rAAV injection and serum collection 
Quantified recombinant viruses were thawed and diluted with TFB2 to achieve 
1x1013 genome copies in 200uL volume. 1ml TB Syringes (BD) were used to inject 
TFB2 diluted viruses at 6 different sites in the quadricep muscles, 3 sites on each 
quadricep muscle. Details of all Aotus nancymae monkeys that were included in the 
protocol are listed in Table 1. Post i.m. injections, blood was drawn at different time 
points (Table 2) through either femoral vein or great saphenous vein bleeds. Sera was 





Quantification of Monoclonal antibodies by ELISA 
Quantification of human anti-CSP antibodies are conducted as previously 
described (Deal 2014). Each well of the 96-well ELISA plate (2HB Immunlon Flat 
Bottom Microtiter plate) was coated with 100μL of rCSP purified from MR-272 at 
0.5ug/mL in PBS overnight at 4°C. The unattached rCSP was washed away with 200uL 
of PBS-Tween three times, and 200uL of PBS three times. 10% FBS, 0.05% Tween PBS 
solution was used as a block and incubated at 4°C overnight. The plate was again washed 
with PBS-T and PBS. In 96X Serocluster Plates (Costar), sera were diluted in the 
blocking solution starting at 1:1500 and diluted by 3-fold. 100uL of the diluted sample 
sera were then transferred to the ELISA plate and incubated at room temperature (RT) for 
1 hour. Followed by another 3X wash with both PBS-T and PBS, 100uL of Human 
Kappa light chain antibody (Bethyl A80-115P) diluted by the blocking solution in 
1:10,000 was added and incubated at RT for 1 hour. The ELISA plate was washed for the 
last time with PBS-T and PBS and 100uL of BD OptEIA TMB substrate reagent mixture 
was added and incubated at RT for 15 minutes, in the dark. After 15 minutes, 100μL of 
4N sulfuric acid was added to halt the of substrate-enzyme reaction. ELISA plates were 
measured by Multiskan MCC (Thermo Fisher Scientific) plate reader with Accent 
Software for Multiskan (Thermo Fisher Scientific) at 450nm wavelength. The human 
anti-CSP antibodies in the Aotus sera were detected with an identical protocol.   
 
Transgenic P.berghei/P.falciparum Challenge in Mice 
Mice were challenged with transgenic murine malaria, P.berghei, expressing 
P.falciparum CSP (Pb/PfCSP Nardin strain) that was provided by the Zavala laboratory. 
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The Johns Hopkins Parasite Core provided the Pb/Pf Nardin strain infected Anopheles 
stephensii mosquitoes for challenge. The transgenic parasite challenge was conducted 
with mosquitoes that were 21-24 days post blood feed.   
Prior to the malaria parasite challenge, 15-20 Pb/Pf Nardin strain infected A. 
stephensii mosquitoes were temporarily knocked out in the -20, placed in the ethanol and 
transferred to PBS. The mosquitoes’ salivary glands be dissected under the microscope 
with 26G PrecisionGlide Needle (BD) and were checked for the presence of parasites 
under the microscope. The challenge was only conducted if the rate of sporozoite 
infectivity of the salivary gland was over 80%. The day prior to the challenge, 8-12 
infected mosquitoes were separated into each paper cup with open netting on the top for 
each mouse. The infected mosquitoes were starved overnight and were dehydrated 4 
hours prior to the challenge.  
In order to preserve natural route of infection, each mouse was placed on a paper 
cup netting after anesthetization with 100-120uL of Ketamine that was given 
intraperitoneally. The mice were placed on the paper cup netting for base 10 minutes with 
occasional blow of CO2. After the feed on the mice, the infected mosquitoes in each 
paper cup was knocked down, killed in 70% ethanol and its midgut was dissected to 
determine the number of mosquitoes that fed on each mouse.  
To determine days to patency, starting from day 4 post mosquito feed, blood 
smears were made from tail bleeds to observe level of parasitemia. The blood smears 
were fixed on glass slides by methanol and stained with 10% Giemsa stain (Sigma-
Aldrich) for 30 minutes. The blood smear was observed under the 100X oil-emulsion 
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microscope. After 2 days of confirmation of parasitemia, the mice were euthanized. 










































Figure 4. AAV Transfection Scheme taken from Saraiva et al. [73] 
The transfer vector (VIP), pHELP, and pAAV plasmids are transfected in a 293 cells that express 
the E1a gene. The VIP is replicated and are encapsidated in the AAV capsid that have been 
translated by pHELP and pAAV. The newly formed rAAVs are purified through CsCl gradients 




















Though RTS,S/AS01, the first malaria vaccine, did not provide a high protective 
efficacy in areas of endemicity [36] it has provided valuable information on antigen 
exposure in naïve population and semi-immune population that elicit different immune 
responses [11]. It also provided additional evidence on the major correlate of protection, 
the presence of the antibody as the biggest factor in prevention of malaria infection [36].   
The VIP system provides the possibility of alternative method in providing 
proven antibodies that neutralize the pathogen [62-65, 67]. In a study that used the 
rAAV-VIP system to deliver CSP- binding and sporozoite neutralizing 2A10 and 2C11 
antibodies, the antibodies were able to provide sterile immunity in 60% of the mice, and 
the protective efficacy was reflective of antibody level expressed by the VIP system. 
Because the expression kinetics of the antibody are a major factor in achieving sterile 
immunity, investigations into further VIP-antibody pairing could provide invaluable 
information on the VIP system and ideal candidates for the most efficient antibody 
delivery.  
In our experiments, we have cloned the newly described CIS43 and MGU-12 VH 
and VK inserts into the existing VIP plasmid that have 2A10 VH and VK inserts. The 
CIS43, MGU-12 as well as existing 2A10 and b12 VIP plasmids were evaluated by 
expression assay in vitro, encoded in rAAV2/8 vector and transduced in mice. The 
expression of each VIP was evaluated by conducting ELISA to detect human monoclonal 
antibodies with anti-CSP activity. In the ELISA, the sera are diluted 3-fold starting from 
1:1500 to 1:3,280,500. A sample’s dilution was considered ‘positive’ if the optical 
density value was 2X the amount of background signal. By recording the highest dilution 
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of sample that was considered ‘positive’ each week, we were able to see the VIP 
expression kinetics throughout an 8-week period and compare them within different VIP 
expressions.  
After week 8, all mice were challenged by bites from Anopheles stephensii 
mosquitoes infected with transgenic Pb/PfCSP parasites. Parasitemia was confirmed by 
blood smear to day 14 post challenge.  
To evaluate VIP expression in nonhuman primates (NHP) we transduced Aotus 
monkeys with protective 2A10 VIP construct via efficient rAAV2/1 (rep/cap) vector 
(data unpublished) and observed the VIP expression kinetics through ELISA.   
 
Vector Plasmid Construct and Cloning 
 
As described, the monoclonal CIS43 [68] and MGU12 [69] antibodies bind 
upstream of the NANP tetramer repeat region, a region termed the junctional region. 
CIS43 binds to an epitope 15-mer N’-NPDPNANPNVDPNAN-C’ (Peptide 21) and 
MGU12 binds to 15-mer N’-KQPADGNPDPNANPN-C’ (NPDP15) upstream of the 
central repeat region that gives a different dimension of neutralization uncharted so far.  
The first VIP system for the CSP region of the sporozoite used the VIP backbone 
[62]  and the 2A10 and 2C11 [74] variable heavy (VH) and variable light/kappa (VK) 
variable region sequences were cloned as described [62, 65]. To clone the variable 
regions (referred to as inserts) of the two new antibodies into the 2A10 VIP vector, DNA 
encoding the published Heavy (VH) and Light or Kappa (VK) inserts were first 
synthesized by Thermo Fisher Invitrogen GeneArt Gene Synthesis. In VIP vectors, the 
variable regions of the heavy and kappa inserts are flanked by endonuclease restriction 
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sites, NotI and AgeI flank the VH region and NsiI and PstI flank the VK region.  By 
different endonuclease reaction and ligation methods, the 2A10 variable insert regions 
were replaced with the new inserts, as to maintain the functional domains previously 
described [62, 65].  
Using the endonuclease and ligase reactions, the CIS43 VH and VK regions were 
cloned into the VIP plasmids, replacing the 2A10 VH and VK regions. CIS43 VH region 
was first cloned successfully and confirmed through an additional DraIII restriction site 
that was present in the CIS43 VH region but not 2A10 VH region (Fig. 5A). DraIII 
digestion cleaved the CIS43VH-2A10 Vk plasmid into two fragments, 4444bp and 1986bp 
in size. However, the cloning procedure for CIS43 VK did not yield the desired plasmid, 
therefore Gibson Assembly Kit (New England BioLabs) was used to for VK cloning. The 
cloning of CIS43 VK region into the VIP backbone presented an extra endonuclease KpnI 
restriction site that would give rise to 2 plasmid fragments 5198bp and 1141bp. For the 
confirmation of the complete integration of both CIS43 VH and VK regions, randomly 
chosen colony lysates after the Gibson Assembly were tested with both DraIII and KpnI 
endonuclease to confirm the number of fragment and sizes (Fig.5B). To test for any rare 
occurrences of mutation during the Gibson Assembly procedure, the restriction enzyme-
confirmed CIS43 VIP plasmid was sent to the Johns Hopkins Sequencing Core and 
confirmed expected integration of CIS43 VH and VK inserts and ligation sites. 
MGU-12 VH and VK regions were cloned into the 2A10-VIP plasmid at the same 
time by G. Ketner using the Gibson Assembly Kit. Because the restriction sites in 
variable regions of MGU-12 VH and VK would give rise to equal number of fragments 
and sizes that were too similar to the 2A10-VIP plasmid, the VH and VK insert and 
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ligation sites were sequenced by the Johns Hopkins Sequencing Core and confirmed 
expected integration of MGU-12 VH and VK inserts and ligation sites. 
 
Comparative Functionality of Newly synthesized VIP Plasmid to 2A10 VIP 
Plasmid in vitro 
 
To compare the functionality of the new VIP plasmids, we conducted expression 
assays on 293T cells in parallel with 2A10 VIP plasmids. Because the 2A10 VIP 
plasmids have been validated in vitro and vivo, 2A10 VIP plasmid was used as a standard 
for testing the expression of VIP in 293T cell-line. From the expression assay, CIS43 VIP 
plasmid had comparable amounts of hIgG secretion while MGU-12 had more than 2-fold 
production of hIgG (Fig.6). The expression rate of two additional antibody-VIP plasmid 
was also tested. The CIS43-EIVL VIP plasmid is a construct of CIS43 antibody with 
amino acids EIVL substituted for the native amino acids DIQM at the amino terminus of 
the Vk region in an attempt to increase antibody expression (GK, personal 
communication). Anc-2A10 is an Aotus nancymae antibody with CH and CK regions of 
2A10 replaced with the corresponding regions of A. nancymaae IgG (G. Ketner, personal 
communication). It was hypothesized that IgG with the natural Aotus antibody constant 
regions might be more stable in vivo, and that the expressed antibodies may accumulate 
to higher concentration in the Aotus. However, the CIS43-EIVL and Aotus-2A10 
additional VIP plasmid constructs had very low expression in comparison to 2A10 VIP 





Evaluation of VIP expression kinetics in Murine Model 
 
To evaluate the VIP expression kinetics in vivo, C57/BL6 mice were transduced 
with rAAV2/8-CIS43 (n=8) and  rAAV2/8-MGU-12 (n=9), with  rAAV2/8-2A10 as anti-
CSP positive control (n=10) and rAAV2/8-b12 (n=10) as anti-CSP negative control 
(n=10) as 2A10 and b12 VIP was tested previously [62, 65]. Viruses were quantified 
using qPCR and diluted with TFB2 to achieve 1x1011 genome copies (GC) in 100uL. 4-6 
week old female C57BL6 mice were injected in the right gastrocnemius muscle via 
insulin syringes.  Blood was drawn every week from Week 0 to Week 8 through cheek-
bleeds and sera were separated and stored at -80°C. The VIP expression, the anti-CSP 
antibody was detected by capture with recombinant CSP (rCSP) and HRP-conjugated 
anti human kappa light chain. Sera were diluted from 1:1,500 in a 3-fold manner to 
capture the highest dilution that gives twice the amount of background signal in 450nm 
wavelength (Fig.7).  
The highest average anti-CSP antibody expression was from rAAV2/8-MGU-12 
(1:1,235,093) (Table 1A), while rAAV2/8-CIS43 showed the lowest average expression 
of anti-CSP antibody (1:210,230) (Table 1A). From the results, some mice transduced 
with CIS43 VIP, were considered negative until week 5 and had a rising titer (Fig 7b), 
however, in these mice, there was detectable signal above the background, however it 
was short of the threshold for being ‘positive’ at the lowest dilution of 1:1500. It can be 
suggested that dilutions lower than 1:1,500 could properly evaluate the concentration of 
anti-CSP antibody in these mice. The control b12 VIP mice did not produce any 
detectable concentration of anti-CSP antibody throughout the experimental period. 
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Transgenic P.b/P.fCSP Challenge in Mouse 
 
To evaluate the VIP of its protective efficacy against CSP of Plasmodium 
falciparum in mice, all mice were challenged with the transgenic mouse malaria -
Plasmodium berghei with the Plasmodium falciparum CSP on its surface.  For the 
challenge, A.stephensii mosquitoes were blood-fed on blood-stage Pb/PfCSP parasites 
21-24 days before the challenge. A day before the challenge, salivary glands of randomly 
chosen female mosquitoes from the parasite fed mosquito cages were dissected and 
evaluated for the presence of sporozoites in the salivary gland. In both challenges, the 
salivary gland infectivity rate of the mosquitoes was over 80% to ensure injection of 
sporozoites into each mice. 8 weeks post-transduction of rAAV-VIP, each mice was 
anesthetized with ~100uL of ketamine and were exposed to overnight-starved and 
dehydrated female Anopheles stephensii mosquitoes.  
7-11 mosquitoes were placed in individually netted cups and mice were laid on 
the netted cups until there was visual confirmation of mosquitoes fed over 50%.  Post 
mosquito feeds, all mosquito midgut was dissected to record the number of mosquitoes 
that fed on each mouse. Between 4-11 mosquitoes fed on each mouse.  
 
Evaluation of VIP expression kinetics in Murine Model #2 
 
After analysis of the first transduction experiment, a replicate experiment was 
conducted with the same rAAV-VIP vectors. However, due to relatively low levels of 
anti-CSP hIgG reciprocal dilutions (2A10 – 1:210,230, CIS43 – 46,462, and MGU-12 – 
1,235,093)(Table 1A) and protection (10% in only the MGU-12 group)(Fig. 7C) from the 
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first transduction, 3x1011 GC were transduced in mice. Because there was a stable 
expression of antibody after week 2-3, half of the VIP group were bled on either week 1,3 
and 8 or week 2, 4 and 8 to capture expression before and after stabilization as well as 
expression right before the challenge. For the second transduction, the highest average 
reciprocal titer of anti-CSP antibody was again, rAAV2/8-MGU-12 (1:3,280,500), while 
rAAV2/8-CIS43 consistently showed the lowest concentration of anti-CSP antibody (1: 
465,291) (Table 1B).  
 The anti-CSP reciprocal titer for all mice transduced with MGU-12 reached the 
highest dilution in the ELISA assay (1: 3,280,500), and it can be suggested that the mice 
had higher titers than tested in our ELISA. The negative-control mice transduced with 
b12 VIP did not produce any detectable concentration of anti-CSP antibody throughout 
the experimental period.   
 These mice were also challenged with the transgenic mouse malaria -Plasmodium 
berghei with the Plasmodium falciparum CSP on its surface (Pb/PfCSP). The challenge 
protocol was identical to the first transduction and between 4-11 mosquitoes fed on each 
mice.  
Protection from transgenic P.b/P.fCSP Challenge in Mouse 
 
Due to differences in rAAV-VIP GC, the Kaplan-Meier curve was analyzed 
separately for the replicate challenges. For the first Pb/PfCSP challenge only MGU-12 
VIP group showed 10% protection from parasitemia. In the second Pb/PfCSP challenge, 
CIS43-VIP group showed 10% protection and MGU-12-VIP group showed 50% 
protection from parasitemia. Both challenges had 100% observed parasitemia from blood 
smears of the b12-VIP infection-positive control group as well as 2A10-VIP group.  
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Anti-CSP monoclonal antibodies titer in Non-human Primates transduced with 
AAV1 
 
The Aotus monkey species are a unique family of monkeys that can be naturally 
infected with human malaria, P. falciparum in its sporozoite form [70]. Vaccine models 
have been studied in Aotus monkeys[72] and are able to sustain the parasite lifecycle 
from sporozoite invasion to transmission through mosquitoes[70]. Because the model can 
replicate P.falciparum sporozoite invasion into the hepatocytes as in humans, it is an 
ideal model to observe effects of monoclonal antibodies against P.falciparum sporozoites. 
 The 6 monkeys, 3 male and 3 female, were transduced with AAV2/1-2A10 VIP 
and observed the antibody kinetics up to week 30. AAV1 showed optimal expression 
efficiency (unpublished data) and was used as the vector for transduction of 2A10-VIP.  
 On the day of infection, the titrated virus was diluted with 0.1M Citrate 10mM 
Tris, pH 8.0 (TFB2) solution for the final volume of 200uL. A total of 1x1013 GC was 
injected into 6 different sites on the quadricep muscles bilaterally, 3 sites per side.  
 Post transduction, the monkeys were bled in weeks 1, 2, 3, 4, 6, 8, 11, 15, 20, 25, 
30. Identical ELISA protocol for mice was used for the Aotus detection of anti-CSP 
antibody. 2 monkeys and 1 male and 1 female in different pair/cages showed prolonged 













Figure 5. Confirmation of CIS43VH-2A10VK VIP, and CIS43VH-VK VIP plasmid by 
endonuclease reactions 
(A) The additional DraIII restriction site in the CIS43 VH region cleaved the plasmid into 
two fragments, 4444bp and 1986bp in size compared to a linearized 2A10 VIP. Lane 1-3 
contains plasmid with CIS43 VH and 2A10 VK which results in two fragments. Lane 4 
represents plasmid with 2A10 VH and VK that only have 1 restriction site resulting in a 
linearized plasmid. (B) Confirmation of both CIS43 VH and VK inserts. Lysate 12 and 23 
were digested with either Dra III or KpnI. Lysates with CIS43 VH have 2 restriction sites 
that lead to 2 fragments 4444bp and 1986bp (Lane 2-3). Lysate 12 and 23 were against 
digested with KpnI, which results in 2 fragments in the presence of CIS43VK. Lysate 12 
and 23 show 2 fragments sizes 5198bp and 1141bp that confirms the presence of CIS43 
VK (Lane 5-6). CIS43 VH-2A10VK VIP plasmid was used as a positive control for DraIII 

















































Figure 6. In vitro comparative functionality of the VIP plasmids 
The expression efficiencies of CIS43, MGU-12, CIS43-EIVL VIP and Aotus-antibody 
based 2A10 plasmid was evaluated by comparison of human IgG production to the 2A10 
VIP. The plasmid concentrations were measured by nanodrop and equal amounts of 
plasmids were transfected in 293T cell culture with BioT (Bioland Scientific LLC). The 
supernatant was collected 48 hours post transfection and ELISA was conducted to detect 
levels of monoclonal hIgG. The expression ratio between 2A10 and other antibodies are 
























Table 1. Anti-CSP antibody titers 
 (a) Geometric mean of the reciprocal dilution of the 1st transduction for each VIP group. 
2A10 (n=10), CIS43 (n=8), MGU-12 (n=9), b12 (n=10). (b) Geometric mean of the 
reciprocal dilution of the 2nd transduction for each VIP group. 2A10 (n=10), CIS43 















































 (a) Reciprocal dilution of anti-CSP titer of rAAV-2A10 in individual transduced mice 
weekly over an 8-week period in log scale (n=8). (a) Reciprocal dilution of anti-CSP titer 
of rAAV-CIS43 transduced mice over an 8-week period in log scale (n=9). (c) Reciprocal 
dilution of anti-CSP titer of rAAV-MGU-12 transduced mice over an 8-week period in 
log scale (n=10). The anti-CSP titer of rAAV-b12 transduced mice did not show any 



























































































Figure 8. Second Transduction: Anti-CSP titer in Mice Transduced by rAAV-VIP 
 (a) Reciprocal dilution of anti-CSP antibody titer of rAAV-2A10 transduced mice at 
weeks 1 or 2, 3 or 4 and 8 in a log scale (n=10). (a) Reciprocal dilution of anti-CSP 
antibody titer of rAAV-CIS43 transduced mice at weeks 1 or 2, 3 or 4 and 8 in log scale 
(n=9). (c) Reciprocal dilution of anti-CSP antibody titer of rAAV-MGU-12 transduced 
mice at weeks 1 or 2, 3 or 4 and 8 in a log scale (n=10). The anti-CSP antibody titer of 
























Figure 9. Kaplan-Meier Curve: Days to Patency 
 (a) During the first Pb/PfCSP challenge, protection from patency was observed in 10% 
of the MGU-12-VIP mice and while all other mice showed parasitemia by day 8. (b) In 
the second Pb/PfCSP challenge, protection from patency was observed in 10% of CIS43-
VIP group, and 50% of MGU-12 group. In both replicates, the infection-positive control 
b12-VIP group and 2A10-VIP group had 0% protection from parasitemia observed by 
blood-smears.   
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Figure 10. Monoclonal anti-CSP expression in Aotus monkeys 
The Aotus monkeys were transduced using the 2A10/AAV1 vector and blood was drawn 
from week 0 to week 30 to observe the 2A10-VIP expression. Aotus #86211 and #86563 













Table 2. Aotus Sex and Pair Information 
Anti-CSP Antibody Reciprocal Dilution 
Aotus 
ID 
Week   
1 
Week   
2 
Week    
3 
Week   
4 
Week    
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Plasmodium falciparum is a devastating disease that causes over 240 million 
cases a year especially in developing countries and the major contributor of 266,000 
children deaths under 5 years old reported in 2017 [1]. To control the disease, 276 million 
rapid diagnostic tests, 2.74 billion treatment courses Artemisinin-based combination 
therapy, and overall, $3.1 billion  in resources was used in just 2017 alone to make par 
with the increasing prominence of the disease [1]. Though decades of research on malaria 
research has yielded a licensed RTS,S/AS01 malaria vaccine in 2015, the WHO has only 
recommended the vaccine to a narrow group that have moderate to high malaria 
endemicity. Moreover, the RTS,S/AS01 vaccine efficacy only provides a moderate 
vaccine efficacy (35.9%) in its first year, and wanes off completely by year 5 [36]. 
Though RTS,S/AS01 is a moderately effective vaccine, there is a need for a vaccine with 
improved efficacy as well as extended period of protection to lessen the burden of 
infection and reinfection. 
 From studying and manipulating the immune response against irradiated 
sporozoites in different animal models and humans [13, 41, 42], as well as data from the 
phase 3 clinical trial of RTS,S/AS01, the correlate of protection from sporozoite infection 
was the neutralizing antibody against the CSP antigen [36]. From the data available, 
increased amount of neutralizing antibody for an extended period would serve as an ideal 
vaccine against malaria. We have investigated further on expressing high levels of 
monoclonal antibodies for an extended period by using the VIP system through the AAV 
vector. In mice, the expression of the antibodies directed against the CSP showed allowed 
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high titer of antibodies (~1mg/mL) and maintained the level of antibody titer over a year, 
until the end of the study [65].  
 VIP system is an AAV vector mediated gene transfer that allows for extended 
expression and secretion of neutralizing antibodies into the circulation. In our new 
investigation of VIP system, two ‘improved’ CSP binding antibodies with higher affinity  
targeting a region previously unrecognized [68, 69] was integrated into the AAV-VIP 
system and was evaluated on factors based on mAb expression as well as measure of 
sterile immunity. The second part of the project involved investigation into the viability 
of the AAV-VIP system in a nonhuman primate model that could be used directly to test 
the AAV-VIP against P. falciparum, the human malaria parasite.  
 In characterizing and measuring the expression of the CIS43 [68] and MGU-12 
[69] VIP construct, there was a significant difference in expression levels between 
different antibodies, notably the MGU-12 VIP plasmid expressing more than twice 
(1:2.051) the amount of antibodies than the 2A10-VIP plasmid (Fig. 6) that was already 
documented to express high titers of anti-CSP antibodies [65]. This observation was 
fascinating in two levels, 1) with all components of the VIP system left unedited except 
for the variable segments there was several fold difference in antibody expression in vitro, 
and 2) the tested antibody expression in vivo using the rAAV vector had similar 
correlation as MGU-12-VIP yielded in several fold difference compared to 2A10-VIP 
(210,230:1,235,095 or ~6:1 ratio in the first mouse transduction and 465,291:3,280,500 
or ~7:1 ratio in the second mouse transduction) (Table 1).  
Variable expression level is observed in other antibodies as seen in vitro VIP 
expression data gathered collectively below (Table 2). There is much varied expression 
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of the transgenes between different VIP constructs as well as the animal model. It is also 
evident that expression fluctuates with few amino acid changes in the non-variable region 
as seen from CIS43 VIP, compared to the CIS43 EIVL VIP (Fig. 6). Though the factors 
for mAb expression rate is uncertain, it has been suggested that the variable region 
sequences of the VIP construct can contribute to the expression level of the transgene[67].  
 
Publication Antibody 







































100X lower than in 
mice 













>100 in sera, 
100ng/mL in 
lamina propria 
VRC07 >100 in sera, 
1ug/mL in lamina 
propria 
Table 4. Variable Expression in different VIP constructs 
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 In mice, antibody expression kinetics of rAAV showed stable expression of VIP 
antibodies, though expression titer was varied among different antibody types (Fig. 7 and 
8). The antibody expression peaked between weeks 2-4 and was maintained at similar 
titers until week 8 before the Pb/PfCSP challenge.  
In measuring patency and protection following the Pb/PfCSP challenge, highest 
survival rate was observed in mice group with the highest reciprocal titer (MGU-12, 
1:1,235,093 in first transduction and 1:3,280,500 in second transduction) (Fig.7 and 8). 
The MGU-12 VIP group achieved the highest reciprocal titer tested by ELISA, and of 
those that reached the maximum reciprocal titer of 3.28x106 in the second transduction 
5/10 were protected (Fig. 8C). From both CIS43-VIP groups from two challenges, the 
one mouse that survived the Pb/PfCSP challenge had the second highest anti-CSP 
antibody titer (1:3.65x105) (Fig. 8B). In both the MGU-12 VIP groups from two 
challenges, protection from Pb/PfCSP was only observed in mice with titers at 
1:3.28x106 anti-CSP antibody titer (Fig. 7C and 8C). Though it is not conclusive due to 
low sample size, it could be suggested that lower concentration of CIS43-VIP could elicit 
similar or higher rate of protection than MGU-12 VIP.  In the 2A10-VIP group, the 
antibody titer was much lower than MGU-12, averaging 2.10x105 in the first transduction 
and 4.65x105 in the second transduction (Table 1) and no protection was observed in 
contrast to the past findings.  [65]. Though the main reasons for this result is uncertain, 
factors such as different parasite strain and method for intramuscular injections resulting 
in less efficient infection could elicit low expression and protection, and consistency in 
the control VIP may be needed to further support the finding. In addition, further 
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investigations into actual antibody quantity may reveal the efficacy of the antibody as 
well as efficiency of the rAAV vectors.  
 In transduction of the Aotus monkeys, all 6 monkeys were transduced with AAV1 
VIP vectors that encoded the 2A10 antibody heavy and kappa variable regions. Different 
capsids were tested in Aotus models and showed that AAV1 had the highest capacity 
(unpublished data) to deliver the transgene into the nonhuman primates. In the first 2 
weeks post transduction, all 6 monkeys saw rising anti-CSP hIgG titers (Fig. 10). 
However, from week 3, signs of hIgG decline was evident and by week 6, 3/6 of the 
Aotus (#86211, 86006, 86664) showed no detectable hIgG. At the end of week 30, 2/6 
monkeys still maintained an elevated level (1:2.1x105 in #86211 and 1:1.2x105 in #86563) 
of anti-CSP hIgG (Fig. 10). Though upon stabilization of the transgene expression, the 
level of antibody titer was encouraging, however, the percentage of monkeys that had 
sudden declining titers showed the need for further research in realizing the full potential 
of the VIP system.  
Due to report of pre-existing immunity against ubiquitous AAV[75], efforts in 
optimizing AAV vectors have been explored, which include directed evolution/mutation 
of the capsid, discovery of naturally occurring AAV, rational design of AAV from 
existing strains and in silico design of AAV capsids through computational approaches 
[45]. Development of ‘unseen’ AAV vectors would not only circumvent pre-existing 
immunity, but it could also open doors to developing therapies that require sequential 
delivery or multi-dose or re-administration of transgenes as a booster dose.  
Specific improvements for VIP and antibody transgene delivery have also been 
investigated due to reports of host immune responses that elicit anti-drug antibodies 
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(ADA) in NHP [67, 76, 77]. Progress has also been made against ADA, such as the use 
of pharmacological molecules to such as cyclosporine [67] and rituximab [78] that elicit 
immunosuppression of subjects and allow undisrupted expression and functionality of the 
transgene.  In addition, continuous investigations on antibody structure/affinity are 
ongoing, including discovery of higher affinity antibodies through CHIM [68, 69], 
engineering the structural make-up of antibodies for extended duration of half-life [79, 
80], and expressing cocktail of antibodies targeting different part of the CSP.  
However, as interest in AAV and gene therapy grows, further considerations for 
safety, and cost needs to be considered in the scope of public health. Though an AAV-
based gene therapy products are available, new information on rAAV-induced side 
effects are still unraveling [81] and further investigations on gene- insertion related issues 
[82] have raised an alert for use of AAV in a clinical setting. Therefore, further 
observation, investigation and careful regulation needs to be instituted for drug safety.  
It is also concerning that the cost of the first two approved gene therapy is 
astronomical. According to news sources in the US and Europe, Glybera costs €1 million 
($1.2m) and Luxturna costs $850,000, $425,000 per eye. It is two most expensive drugs 
in the world, and due to its cost, Glybera, which has been licensed since 2012, has only 
had 1 patient and is no longer in the market as there is no demand for the drug. For 
further evaluation of AAV as drugs, propaganda for AAV drug safety and to actually 
influence public health, the pharmaceutical industry needs to make compromises for 
continuation of AAV-based drugs.  
Our current model of the VIP system against the sporozoite stage of P.falciparum 
has shown evidence of efficient delivery vector and demonstrated potent antibodies in 
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achieving sterile immunity. However, further investigations into neutralizing antibodies, 
AAV vectors and challenge models in nonhuman primates are needed to further validate 
the VIP system and to potentially play a part in alleviation of the burden of malaria and 
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